AnaptysBio, Inc.ANABNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-16.97%
↓ 373% below average
Average (39q)
6.22%
Historical baseline
Range
High:68.98%
Low:-51.36%
CAGR
-2.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -16.97% |
| Q2 2025 | -8.15% |
| Q1 2025 | -3.31% |
| Q4 2024 | 0.89% |
| Q3 2024 | 0.51% |
| Q2 2024 | 13.38% |
| Q1 2024 | -9.35% |
| Q4 2023 | 32.34% |
| Q3 2023 | -6.21% |
| Q2 2023 | -5.82% |
| Q1 2023 | 49.56% |
| Q4 2022 | 5.94% |
| Q3 2022 | 5.85% |
| Q2 2022 | -7.43% |
| Q1 2022 | -15.91% |
| Q4 2021 | 20.50% |
| Q3 2021 | -12.22% |
| Q2 2021 | 4.67% |
| Q1 2021 | 12.14% |
| Q4 2020 | 10.36% |
| Q3 2020 | 8.88% |
| Q2 2020 | -14.40% |
| Q1 2020 | -2.14% |
| Q4 2019 | -28.42% |
| Q3 2019 | 9.44% |
| Q2 2019 | 32.57% |
| Q1 2019 | 29.59% |
| Q4 2018 | -10.98% |
| Q3 2018 | 68.98% |
| Q2 2018 | -10.39% |
| Q1 2018 | 53.26% |
| Q4 2017 | 11.73% |
| Q3 2017 | -11.63% |
| Q2 2017 | -8.55% |
| Q1 2017 | 41.87% |
| Q4 2016 | -7.19% |
| Q3 2016 | 21.50% |
| Q2 2016 | 11.47% |
| Q1 2016 | 33.99% |
| Q4 2015 | -51.36% |